Strategy
Define regulatory pathways, market priorities, sequencing, and submission strategy based on portfolio goals and evolving health authority requirements.
150+
markets where we manage submissions for a top-10 pharma
70%
faster first draft creation
99.9%
submission quality / right-first-time publishing
Submission season looks the same everywhere. Writers reconcile documents at midnight. Publishing chases formatting defects. The calendar assumes nothing slips, and something always slips. Heroics get the file out. They also burn out the people you need for the questions that follow.
Meanwhile the portfolio grows and every agency changes its rules on its own schedule. Hiring your way out arrives late and leaves no knowledge behind.
As AI and automation take on more repeatable regulatory activities, teams can focus more on scientific judgment, regulatory strategy, and complex decision-making. The value of regulatory expertise increasingly lies in applying judgment, not managing process.
Health authorities are moving toward structured data submissions and cloud review. Sponsors whose content is already componentized will glide through the transition. The rest rebuild under deadline.
Quality cannot depend only on checks at the end of the submission process. Earlier gap identification, stronger content governance, and preparation for health authority questions can help teams address issues before filing.
Portfolio peaks and market expansion demand capacity that flexes by quarter. The CoE model with embedded AI beats permanent headcount on cost, speed, and knowledge retention.
Every shift supports regulatory teams that apply judgment where it matters most. Automation and expertise work together.
Define regulatory pathways, market priorities, sequencing, and submission strategy based on portfolio goals and evolving health authority requirements.
Answer feeds plan. Every query makes the next submission sharper.
Explore how AI enhances medical writing while managing risks through human oversight, quality, and regulatory trust.
See how a global pharma cut information gathering by 55% and improved submission success with AI-powered intelligence.
Learn how governance, operating models, and technology enable consistent, compliant labeling across global markets.
Market-specific regulatory requirements, pathway design, regulatory strategy, and submission sequencing.
CMC regulatory strategy and support across development, submissions, and lifecycle activities.
AI-assisted authoring across Common Technical Document modules, submission content, responses, and lifecycle documents.
Submission planning and management, electronic Common Technical Document compilation, publishing, validation, and dispatch across 150+ markets, including health authority query and response coordination.
Label lifecycle management and packaging artwork to support consistency across markets.
Anonymization, redaction, lay summaries, and RIM modernization.
Acceleration comes from structured content, AI-assisted authoring, automated publishing, and submission planning that designs out rework.
Indegene runs all four as one engine, with dossier components assembled in days.
First-cycle approval means the agency approves without a complete response letter, saving a full review cycle that can span many months.
Indegene builds submissions for first-cycle quality through gap analysis, predicted queries, and rehearsed responses.
AI turns regulatory writing into intelligent assembly from governed source content, with human experts focused on judgment and strategy.
Indegene embeds this in its NEXT platform with expert review at every gate.
Outsourcing vendors sell hours.
Indegene runs regulatory as a governed engine with committed dates, audit-clean quality, and fees tied to filing and approval milestones.
Bring us your submission calendar for the next 18 months. Within 2 weeks, you will have a gap analysis, a compression plan, and committed file dates.